Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Combined With Omalizumab in Bullous Pemphigoid
NCT04128176Phase 3Withdrawn
- Sponsor
- University of California, Davis
- Start
- Mar 2017
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in Bullous Pemphigoid (BP), sponsored by University of California, Davis. Planned start Mar 2017; status: withdrawn.
02
Drugs
omalizumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT04128176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128176.